A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Feb 5, 2014

Astellas: Reorganization of Astellas’ Global Management Structure

Read more about Astellas: Reorganization of Astellas’ Global Management Structure
Feb 2, 2014

AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib

Phase 2 Colorectal Cancer Study Discontinued AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014

CAMBRIDGE, MASS. and TOKYO, JAPAN, February 14, 2014 – AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and...

Read more about AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib
Jan 28, 2014

MEDIVATION AND ASTELLAS ANNOUNCE FINAL RESULTS FROM THE PHASE 3 PREVAIL TRIAL OF ENZALUTAMIDE IN MEN WITH METASTATIC PROSTATE CANCER PROGRESSING ON ANDROGEN DEPRIVATION THERAPY

SAN FRANCISCO, CA AND TOKYO, JAPAN – January 28, 2014 – Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced final results on the primary and secondary efficacy...

Read more about MEDIVATION AND ASTELLAS ANNOUNCE FINAL RESULTS FROM THE PHASE 3 PREVAIL TRIAL OF ENZALUTAMIDE IN MEN WITH METASTATIC PROSTATE CANCER PROGRESSING ON ANDROGEN DEPRIVATION THERAPY
Jan 17, 2014

Approval of Suglat® Tablets, a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan

TOKYO, January 17, 2014 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced today that it has obtained the marketing approval of selective SGLT2...

Read more about Approval of Suglat® Tablets, a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan
Jan 15, 2014

Astellas Pharma: Launches Irribow® OD Tablets in Japan for Diarrhea-predominant Irritable Bowel Syndrome

Tokyo, January 15, 2014 - Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that the orally disintegrating tablet “Irribow® OD 1) Tablets...

Read more about Astellas Pharma: Launches Irribow® OD Tablets in Japan for Diarrhea-predominant Irritable Bowel Syndrome
Jan 15, 2014

Astellas and UMN Announce Summary Results in Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374

Astellas Pharma Inc. (TSE: 4503; Headquaters: Tokyo; President & CEO: Yoshihiko Hatanaka) and UMN Pharma Inc. (TSE: 4585；Headquaters: Akita; CEO: Tatsuyoshi Hirano) today announced that the...

Read more about Astellas and UMN Announce Summary Results in Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374
Jan 6, 2014

Transfer of Astellas’ Fermentation Research-Related Assets to Taiho Pharmaceutical

Read more about Transfer of Astellas’ Fermentation Research-Related Assets to Taiho Pharmaceutical
Jan 6, 2014

ASTELLAS TO FORM STRATEGIC PARTNERSHIP WITH CLEARPATH TO BUILD VACCINE PORTFOLIO　-In-license Vaccine Technology for Respiratory Syncytial Virus (RSV) from Mymetics-

Tokyo, Japan; Rockville, MD; and Epalinges, Switzerland – January 6, 2014 – Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic...

Read more about ASTELLAS TO FORM STRATEGIC PARTNERSHIP WITH CLEARPATH TO BUILD VACCINE PORTFOLIO　-In-license Vaccine Technology for Respiratory Syncytial Virus (RSV) from Mymetics-
Dec 25, 2013

Astellas and IBL Concludes Co-Research Agreement Regarding Pharmaceutical Applications of Recombinant Human Proteins Made Using transgenic Silkworms

Tokyo, December 25, 2013 - Astellas Pharma Inc. (“Astellas”) and Immuno-Biological Laboratories Co., Ltd. (“IBL”) today announced that they have concluded a collaborative research...

Read more about Astellas and IBL Concludes Co-Research Agreement Regarding Pharmaceutical Applications of Recombinant Human Proteins Made Using transgenic Silkworms
Dec 20, 2013

Approval of Additional Indication for Hypnosedative, Dormicum® in Japan

Tokyo, December 20, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) announced the approval of an additional indication for hypnosedative,...

Read more about Approval of Additional Indication for Hypnosedative, Dormicum® in Japan

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts